Repligen Corp (NASDAQ:RGEN)
CAPS Rating:
A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.
Market-Beating Community Intelligence
A biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases of the central nervous system.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Repligen gets a green thumb for flirting with the one year low on lousy results of their phase III trial of secretin as an adjunct for pancreatic MRI. Disappointing I guess, but I don't know about a 20% haircut on a stock already down 15% from recent highs. The company will likely continue to maintain cash flows even through anemic 5M quarterly revenues and lazy spending on the phase IIb trial of (yawn) uridine for bipolar disorder. Is this the most boring baby biotech around? Possibly. So why am I still writing this pitch? Trying to think of a reason why this stock will go back up. OK, because it did before. Wannafightaboudit?
Just sold the 5000 shares I bought on 5/11 at 3.25 (http://caps.fool.com/Blogs/ViewPost.aspx?bpid=389896&t=01007366137242330765) for 3.63. GBMB profit of $1900.
Let me try that link once more:
http://caps.fool.com/Blogs/ViewPost.aspx?bpid=389896&t=01007366137242330765